The acquisition adds technology for stroke prevention to Boston Scientific’s vascular portfolio. The TCAR system gained FDA approval in 2015 and is supported by several clinical studies ...

Boston Scientific (NYSE:BSX) issued an urgent field safety notice to warn of a software anomaly with its Avvigo+ guidance ...

Boston Scientific Corporation announced the close of its acquisition of Silk Road Medical, Inc. the developer of transcarotid ...

DELRAY BEACH, Fla. , Sept. 12, 2024 /PRNewswire/ -- The vascular stents market is anticipated to grow from USD 11.4 billion ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of California medical ...

Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX ...

While existing treatment options for blocked carotid arteries include stents and surgery ... disease," said Cat Jennings, Boston Scientific's president of vascular and peripheral interventions.

The WallFlex Biliary RX uncovered stent was cleared by ... RX Stenting System for use in the vascular system have not been established. About Boston Scientific Boston Scientific is a worldwide ...

The disputes involved several coronary stent products including Cordis's Cypher stent and Boston Scientific's Liberte ... and manufacture of interventional vascular technology.

Boston Scientific (NYSE: BSX) announced today that it completed its $1.16 billion acquisition of Silk Road Medical ...

The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This growth ...